AskBio Phase Ib trial of AB-1005 gene therapy in patients

Berlin, Germany/Research Triangle Park, North Carolina, USA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (AAV2-GDNF), an...

Related Keywords

United States ,United Kingdom ,Berlin ,Germany ,North Carolina ,Research Triangle Park ,Edinburgh ,City Of ,Scotland ,Krystof Bankiewicz ,Christian Rommel ,Bayer Ag ,Head Of Research ,Parkinson Foundation ,Linkedin ,Trademark Office ,Asklepios Biopharmaceutical Inc ,Germany Research Triangle Park ,Brain Neurotherapy Bio Inc ,Drug Administration ,Asklepios Biopharmaceutical ,Scientific Chair ,Executive Committee ,Pharmaceuticals Division ,Treatment Emergent Adverse Events ,Movement Disorder Society ,Unified Parkinson ,Disease Rating Scale ,United States Food ,United States Patent ,Accessed December ,Nc Askbio ,Askbio ,Enetherapy ,Player ,Arkinsonsdisease ,